학술논문
REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES
Document Type
Abstract
Author
Source
In Journal of the American College of Cardiology 7 March 2023 81(8) Supplement:1121-1121
Subject
Language
ISSN
0735-1097